Showing 3571-3580 of 4062 results for "".
- Ocular Therapeutix to Present Preclinical and Clinical Data at ARVOhttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-arvo/2479146/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. With the ARVO 2021 Annual Meeting being moved to a virtual format, video-recorded presentations are scheduled to become available online at ARVOLearn o
- New Contact Lens Update Focuses on Ocular Allergyhttps://modernod.com/news/new-contact-lens-update-focuses-on-ocular-allergy/2479141/The Centre for Ocular Research & Education (CORE) has published issue number 59 of its free online education magazine,
- Stealth BioTherapeutics Announces Poster Presentation at ARVOhttps://modernod.com/news/stealth-biotherapeutics-announces-poster-presentation-at-arvo/2479132/Stealth BioTherapeutics announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is being held May 1-7, 2021. The poster showcases
- Nidek Marks 50th Anniversary and Renews Logohttps://modernod.com/news/nidek-marks-50th-anniversary-and-renews-logo/2479104/Nidek will mark its 50th anniversary on August 8th, 2021. To mark this milestone, the company has renewed its logo. While this symbol con
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- Aerie Pharmaceuticals Receives Marketing Authorization of Roclanda in Great Britainhttps://modernod.com/news/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-in-great-britain/2479089/Aerie Pharmaceuticals announced that Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops solution (latanoprost + netarsudil) has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Roclanda is indicated for the reduction of el
- Allergan Launches New Consumer Ad Campaign for Restasishttps://modernod.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021. Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- Infectious Disease Researcher Appointed Inaugural Chief Scientific Officer at Mass Eye and Earhttps://modernod.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/Michael S. Gilmore, PhD, a microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear. Dr. Gilmore will assume the role on May 1, 2021. He has served as Director of the Infectious Disease
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt